AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).
Last trade$45.20
Day change-$0.53 (-1.16%)
Day range$44.99 – $47.28
Volume361,165
Market cap$1.36B
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$1.36B
Price / earnings
16.24×
Price / book
65.3×
Price / sales
4.67×
EV / sales
4.2×
EV / EBITDA
6.15×
Profitability
Earnings per share
$2.82
Return on assets
27.27%
Return on equity
402.09%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
8.4×
Quick ratio
8.4×
Cash ratio
6.04×
Cash flow
Price / cash flow
40.29×
Price / free cash flow
40.31×
Free cash flow
$33.73M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for ANAB, quarterly periods
Line item
Q1 FY2027 Sep 30, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q1 FY2026 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Q3 FY2024 Sep 30, 2024
Revenue
$30.27M
$108.25M
$76.32M
$76.32M
$22.26M
$27.77M
$43.11M
$30.02M
Cost of revenue
$0
$0
$0
$0
$0
$0
$0
$0
Gross profit
$30.27M
$108.25M
$76.32M
$76.32M
$22.26M
$27.77M
$43.11M
$30.02M
Selling, general and administrative
$11.64M
$15.79M
$10.21M
$1.08M
$10.61M
$14.13M
$10.19M
$10.56M
Research and development
-$1.27M
$25.56M
$31.41M
-$2.04M
$37.82M
$41.18M
$42.59M
$42.21M
Total operating expenses
$10.37M
$41.35M
$41.62M
-$952K
$48.43M
$55.31M
$52.78M
$52.77M
Operating income
$19.91M
$66.9M
$34.7M
$77.27M
-$26.17M
-$27.54M
-$9.67M
-$22.76M
Interest expense
-$18.74M
-$19.71M
-$22.52M
-$22.52M
-$19.61M
-$18.06M
-$17.4M
-$15.41M
Income before taxes
$3.27M
$49.7M
$15.11M
$56.62M
-$38.59M
-$39.29M
-$21.79M
-$32.85M
Income taxes
-$608K
$81K
$0
$269K
$39K
$44K
-$6K
$0
Net income
$3.88M
$49.61M
$15.11M
$15.11M
-$38.63M
-$39.33M
-$21.78M
-$32.85M
Net income attributable to common shareholders
$3.88M
$49.61M
$15.11M
$15.11M
-$38.63M
-$39.33M
-$21.78M
-$32.85M
EBITDA
$19.91M
$67.03M
$34.84M
$77.28M
-$26.03M
-$27.39M
-$9.53M
-$22.61M
Basic earnings per share
$0.13
$1.79
$0.54
$0.54
-$1.34
-$1.28
-$0.71
-$1.14
Diluted earnings per share
$0.11
$1.87
$0.52
$0.52
-$1.34
-$1.28
-$0.71
-$1.14
Recent news
Company coverage with links to the original publishers.
AnaptysBio reported quarterly earnings of $0.11 per share, missing consensus estimates of $0.41 and representing a 73.17% earnings surprise. Revenue declined to $30.27 million from $76.32 million year-over-year, missing estimates by 5.65%. The stock received a Zacks Rank #3 (Hold) rating and is expected to perform in line with the market, having underperformed the S&P 500 by 10.7% year-to-date.
EyePoint (EYPT) reported a quarterly loss of $1.07 per share, missing the consensus estimate of $0.88, representing a -21.59% earnings surprise. The company's stock has declined 98.1% year-to-date versus the S&P 500's 11.3% gain. Despite beating revenue estimates, the company maintains a Zacks Rank #3 (Hold) rating with mixed estimate revisions. AnaptysBio (ANAB), a peer in the Medical - Biomedical and Genetics industry, is expected to report earnings of $0.41 per share with revenues down 58% year-over-year.
Arcutis Biotherapeutics is expected to report Q3 2026 earnings on November 4, with consensus estimates of $0.17 EPS (up 183.3% YoY) and $141.64M revenue (up 42.8% YoY). The company has a positive Earnings ESP of +15.39% combined with a Zacks Rank #3, suggesting a likely earnings beat. The company has beaten consensus estimates in 3 of the last 4 quarters.
AnaptysBio (ANAB) is expected to beat consensus earnings estimates for Q3 2026 with a positive Earnings ESP of +23.39% and Zacks Rank #3. The company is projected to report EPS of $0.41 (down 21.2% YoY) and revenues of $32.09 million (down 58% YoY). Recent estimate revisions have been bullish, with the consensus EPS revised 15.02% higher over the last 30 days. The company has beaten consensus estimates in 3 of the last 4 quarters.
GSK received FDA approval for Jemperli (dostarlimab) as the first immunotherapy for adults with stage II and III MSI-H/dMMR locally advanced rectal cancer. The AZUR-1 trial showed 68% of patients achieved sustained clinical complete responses at 12 months without surgery, with no disease recurrences reported among responders after median follow-up of over 2 years. The approval could help eligible patients avoid chemotherapy, radiation, and surgery.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.